Accessibility Menu
Tonix Pharmaceuticals Stock Quote

Tonix Pharmaceuticals (NASDAQ: TNXP)

$18.87
(-4.2%)
-0.83
Price as of October 22, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$18.88
Daily Change
(-4.2%) $0.83
Day's Range
$18.53 - $19.71
Previous Close
$18.88
Open
$19.58
Beta
1.31
Volume
715,242
Average Volume
1,444,055
Market Cap
165.5M
Market Cap / Employee
$18.88M
52wk Range
$6.76 - $130
Revenue
-
Gross Margin
0.09%
Dividend Yield
N/A
EPS
-$1,006.28
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Tonix Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
TNXP+4.89%-100%-86.54%-100%
S&P+14.5%+93.32%+14.09%+398%

Tonix Pharmaceuticals Company Info

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$2.00M-9.5%
Gross Profit-$1.76M25.7%
Gross Margin-87.94%19.1%
Market Cap$264.71M16375.5%
Market Cap / Employee$3.27M0.0%
Employees81-21.4%
Net Income-$28.27M64.1%
EBITDA-$27.81M-62.1%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$125.33M2915.7%
Accounts Receivable$4.22M26.3%
Inventory6-36.7%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.30M-95.2%
Short Term Debt$0.20M-93.7%

Ratios

Q2 2025YOY Change
Return On Assets-63.20%66.4%
Return On Invested Capital-69.15%42.8%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$16.76M-77.1%
Operating Free Cash Flow-$16.21M-71.2%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.310.010.561.379106.71%
Price to Sales0.820.0710.5526.8211626.41%
Price to Tangible Book Value3.4869.280.561.37-97.39%
Enterprise Value to EBITDA0.694.091.62-4.99976.64%
Return on Equity-138.7%-106.1%-91.4%-77.5%-52.52%
Total Debt$8.69M$8.12M$0.56M$0.49M-94.69%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.